207 related articles for article (PubMed ID: 20024842)
1. RNAi for Developing Targeted Therapeutics--CHI's Third Annual Meeting.
Plane G
IDrugs; 2010 Jan; 13(1):20-2. PubMed ID: 20024842
[TBL] [Abstract][Full Text] [Related]
2. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
DeVincenzo JP
Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
[TBL] [Abstract][Full Text] [Related]
3. Ion Channels as Therapeutic Targets--CHI's Fourth Annual Conference.
Thorneloe KS
IDrugs; 2010 Jan; 13(1):16-9. PubMed ID: 20024841
[TBL] [Abstract][Full Text] [Related]
4. RNAi therapeutics: an update on delivery.
Nguyen T; Menocal EM; Harborth J; Fruehauf JH
Curr Opin Mol Ther; 2008 Apr; 10(2):158-67. PubMed ID: 18386228
[TBL] [Abstract][Full Text] [Related]
5. HDAC Inhibitors--CHI's Third Annual Conference.
Rosato RR
IDrugs; 2010 Jan; 13(1):13-5. PubMed ID: 20024840
[TBL] [Abstract][Full Text] [Related]
6. AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 2.
Walker K; Padhiar M
IDrugs; 2010 Jan; 13(1):10-2. PubMed ID: 20024839
[TBL] [Abstract][Full Text] [Related]
7. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
8. Delivering silence: advancements in developing siRNA therapeutics.
Novobrantseva TI; Akinc A; Borodovsky A; de Fougerolles A
Curr Opin Drug Discov Devel; 2008 Mar; 11(2):217-24. PubMed ID: 18283609
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference.
Marblestone JG
IDrugs; 2009 Dec; 12(12):750-3. PubMed ID: 19943215
[TBL] [Abstract][Full Text] [Related]
10. siRNA delivery systems for cancer treatment.
Oh YK; Park TG
Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
[TBL] [Abstract][Full Text] [Related]
11. AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 1.
Walker K; Padhiar M
IDrugs; 2010 Jan; 13(1):7-9. PubMed ID: 20024838
[TBL] [Abstract][Full Text] [Related]
12. Using RNAi in the clinic.
Dev KK
IDrugs; 2006 Apr; 9(4):279-82. PubMed ID: 16596482
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of RNA interference against cancer.
Takeshita F; Ochiya T
Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
[TBL] [Abstract][Full Text] [Related]
14. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
Spagnou S; Miller AD; Keller M
Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
[TBL] [Abstract][Full Text] [Related]
15. Inhalable siRNA: potential as a therapeutic agent in the lungs.
Durcan N; Murphy C; Cryan SA
Mol Pharm; 2008; 5(4):559-66. PubMed ID: 18491918
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
Li SD; Huang L
Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
[TBL] [Abstract][Full Text] [Related]
17. RNA interference strategies as therapy for respiratory viral infections.
DeVincenzo JP
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S118-22. PubMed ID: 18820571
[TBL] [Abstract][Full Text] [Related]
18. Commercial potential of RNAi.
Jain KK
Mol Biosyst; 2006 Nov; 2(11):523-6. PubMed ID: 17216033
[TBL] [Abstract][Full Text] [Related]
19. International Drug Discovery Science and Technology--BIT's Seventh Annual Congress.
Bodovitz S
IDrugs; 2010 Jan; 13(1):23-5. PubMed ID: 20024843
[TBL] [Abstract][Full Text] [Related]
20. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
Akhtar S; Benter I
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
